Marker Therapeutics, Inc. is classed by the SEC under Pharmaceutical Preparations (industry code 2834), based in Houston, TX. Its latest filed balance sheet (2025-12-31) shows total assets of $17 million (its filed statements).
Pre-revenue companyPharmaceutical PreparationsHouston, TXfilings since 19998 of 9 filed, 1 estimated
Three tenses, nine metrics. Unseen metrics stay unseen; the grade never fakes a number. Proxy era: provisional values, marked. Weighed as a pre-revenue company: no meaningful revenue on file yet (industry code 2834), so it is read as a pre-revenue company; the filing read can change it. All three tenses have at least two readings, so the archetype blend applies as printed.
The grade, in three tenses
Headline 4.3 out of ten, 8 of 9 metrics filed and 1 estimated: past 4.6 out of ten, present 4.4 out of ten, future 4.2 out of ten. The past asks what it actually did, the present what it is doing right now, the future what it is set up to do next.
The nine metrics
Surviving crises (past): 4.1 out of ten. 3 warning events since 2017; the latest 2025-08-12. 41st percentile among 497 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
Track record (past): 5.6 out of ten. +59.8% a year over 7 filed years; profitable in 0 of 7. 56th percentile among 324 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
Shareholder treatment (past): 3.6 out of ten. CrossAssetData estimate 3.6/10, confidence 35 of 100 (one part). 36th percentile among 463 sector filers. A CrossAssetData estimate, not a filed reading: one part, confidence 35 of 100; a filing that carries the missing parts replaces this estimate with the filed reading.
Financial health (present): 4.9 out of ten. ROE -72%: lost 72¢ per shareholder dollar. Leverage 12%: owes 12¢ per asset dollar. 49th percentile among 472 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
Industry position (present): 3.7 out of ten. bottom 37% of 314 in its family; net margin -343%. 37th percentile among 314 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
Leadership (present): 4.1 out of ten. bottom 41% of 315 in its family for leadership; chief executive since 2023. 41st percentile among 315 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-09).
Room to expand (future): 6.3 out of ten. top 37% of 272 in its family for room to expand. 63rd percentile among 272 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
Growth drivers (future): 2.4 out of ten. bottom 24% of 307 in its family for growth drivers. 24th percentile among 307 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
Expectations vs reality (future): 4.5 out of ten. bottom 46% of 234 in its family for expectations against reality. 46th percentile among 234 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
The filing record
Newest annual report: Form 10-K filed 2026-03-18 for the period ended 2025-12-31 (on EDGAR). Newest quarterly report: Form 10-Q filed 2026-08-14 for the period ended 2026-06-30 (on EDGAR). Newest results release: Form 8-K filed 2026-03-19 for the period ended 2026-03-18 (on EDGAR). Newest filing: Form 10-Q, 2026-08-14. Filings on record since 1999. Read from EDGAR 2026-10-12.
Where the revenue comes from
Product and service lines in fiscal 2025: Cancer Prevention and Research Institute of Texas Acute Myeloid Leukemia 25%, National Institutes of Health Small Business Innovation Research for Lymphoma Grant 19%, Cprit Pancreatic Grant 16%, National Institutes of Health Small Business Innovation Research 13%, National Institutes of Health Small Business Innovation Research for Pancreatic Cancer 12%, National Institutes of Health National Cancer Institute Grant 11%. As tagged in its annual report (Form 10-K, filed 2026-03-18).
Who runs it
Vera, Juan (Chief Executive Officer); Eansor, Norman David (director); Elms, Steve (director); Knobil, Katharine (director); Corzo, Kathryn Penkus (director). 5 officers and directors have filed their own trades in the last fifteen months, names and titles as filed with the SEC, through 2026-09-30.
Every stock is a company. We grade the company behind the stock. CrossAssetData is a company research product: no investment advice, no price targets, no price predictions; every claim carries its source, and unseen means unseen. The full file draws when the page's script runs: the essentials, the balance sheet, the estimators, the trend, and every filing of the last ten years.